York Capital Management Global Advisors, LLC Autolus Therapeutics PLC Transaction History

York Capital Management Global Advisors, LLC

$455 Million
Q2 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2019 Nov 15, 2019	SELL	$9.79 - $16.72 $236,917 - $404,624	-24,200 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$15.1 - $31.25 $365,420 - $756,250	24,200 New	24,200 $390,000

Others Institutions Holding AUTL

# of Institutions

114

Shares Held

167M

Call Options Held

34.2K

Put Options Held

19.5K

Syncona Portfolio LTD Guernsey, Channel Islands, X0

21.3M
Shares

$77.5 Million
86.45% of portfolio
Blackstone Inc New York, NY

20.5M
Shares

$74.4 Million
0.31% of portfolio
Wellington Management Group LLP Boston, MA

17.9M
Shares

$64.9 Million
0.01% of portfolio
Deep Track Capital, LP Greenwich, CT

15.3M
Shares

$55.4 Million
1.74% of portfolio
Avoro Capital Advisors LLC New York, NY

12.3M
Shares

$44.8 Million
0.59% of portfolio

View Full List

About Autolus Therapeutics plc

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $330M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

More about AUTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of York Capital Management Global Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on York Capital Management Global Advisors, LLC with notifications on news.

Account